Increased all-cause mortality with use of psychotropic medication in dementia patients and controls: A population-based register study

European Neuropsychopharmacology

Volumn 25, Issue 11, 2015, Pages 1906-1913

  Jennum, Poul ^a   Baandrup, Lone ^b   Ibsen, Rikke ^c   Kjellberg, Jakob ^d  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Mental Health Services CPH   (Denmark)

^c I2minds ^*  (Denmark)

^d KORA The Danish Institute for Local and Regional Government Research   (Denmark)

Author keywords

All cause mortality; Antidepressants; Antipsychotics; Benzodiazepines; Dementia; Hypnotics

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; DEMENTIA; DRUG FATALITY; FEMALE; FOLLOW UP; HUMAN; ICD-10; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MIDDLE AGED; POPULATION; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; REGISTER; SURVIVAL; DENMARK; EPIDEMIOLOGY; MORTALITY; PROPORTIONAL HAZARDS MODEL; RISK; SURVIVAL ANALYSIS;

AGED; DEMENTIA; DENMARK; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PROPORTIONAL HAZARDS MODELS; PSYCHOTROPIC DRUGS; REGISTRIES; RISK; SURVIVAL ANALYSIS;

EID: 84947489132     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2015.08.014     Document Type: Article

References (43)

1. Allgulander C. Psychoactive drug use in a general population sample, Sweden: correlates with perceived health, psychiatric diagnoses, and mortality in an automated record-linkage study. Am. J. Public Health 1989, 79:1006-1010.
2. Baandrup L., Jennum P., Lublin H., Glenthoj B. Treatment options for residual insomnia in schizophrenia. Acta Psychiatr. Scand. 2013, 127:81-82.
3. Ballard C., Lana M.M., Theodoulou M., Douglas S., McShane R., Jacoby R., Kossakowski K., Yu L.M., Juszczak E. A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). PLoS. Med. 2008, 5:e76.
4. Bhalerao S., Seyfried L.S., Kim H.M., Chiang C., Kavanagh J., Kales H.C. Mortality risk with the use of atypical antipsychotics in later-life bipolar disorder. J. Geriatr. Psychiatry Neurol. 2012, 25:29-36.
5. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 1987, 40:373-383.
6. Cregg N., Cheng D.C., Karski J.M., Williams W.G., Webb G., Wigle E.D. Morbidity outcome in patients with hypertrophic obstructive cardiomyopathy undergoing cardiac septal myectomy: early-extubation anesthesia versus high-dose opioid anesthesia technique. J. Cardiothorac.Vasc. Anesthesia 1999, 13:47-52.
7. Czekalla J., Kollack-Walker S., Beasley C.M. Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics. J. Clin. Psychiatry 2001, 62(Suppl 2):S35-S40.
8. Declercq T., Petrovic M., Azermai M., Vander S.R., De Sutter A.I., van Driel M.L., Christiaens T. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. Cochrane Database. Syst. Rev. 2013, 3. CD007726.
9. Factor S.A., Feustel P.J., Friedman J.H., Comella C.L., Goetz C.G., Kurlan R., Parsa M., Pfeiffer R. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology 2003, 60:1756-1761.
10. Gueye P.N., Lofaso F., Borron S.W., Mellerio F., Vicaut E., Harf A., Baud F.J. Mechanism of respiratory insufficiency in pure or mixed drug-induced coma involving benzodiazepines. J. Toxicol. Clin. Toxicol. 2002, 40:35-47.
11. Henderson A., Wright M., Pond S.M. Experience with 732 acute overdose patients admitted to an intensive care unit over six years. Med. J. Aust. 1993, 158:28-30.
12. Hessel N.S., de V.N. Diagnostic work-up of socially unacceptable snoring. II. Sleep endoscopy. Eur. Arch. Otorhinolaryngol. 2002, 259:158-161.
13. Honkola J., Hookana E., Malinen S., Kaikkonen K.S., Junttila M.J., Isohanni M., Kortelainen M.L., Huikuri H.V. Psychotropic medications and the risk of sudden cardiac death during an acute coronary event. Eur. Heart J. 2012, 33:745-751.
14. Jennum P., Ibsen R., Knudsen S., Kjellberg J. Comorbidity and mortality of narcolepsy: a controlled retro- and prospective national study. Sleep 2013, 36:835-840.
15. Jennum P., Ibsen R., Pedersen S.W., Kjellberg J. Mortality, health, social and economic consequences of amyotrophic lateral sclerosis: a controlled national study. J. Neurol. 2013, 260:785-793.
16. Jennum P., Kjellberg J., Ibsen R., Bendix T. Health, social, and economic consequences of neck injuries: a controlled national study evaluating societal effects on patients and their partners. Spine 2013, 38:449-457.
17. Kales H.C., Kim H.M., Zivin K., Valenstein M., Seyfried L.S., Chiang C., Cunningham F., Schneider L.S., Blow F.C. Risk of mortality among individual antipsychotics in patients with dementia. Am. J. Psychiatry 2012, 169:71-79.
18. Kales H.C., Valenstein M., Kim H.M., McCarthy J.F., Ganoczy D., Cunningham F., Blow F.C. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am. J. Psychiatry 2007, 164:1568-1576.
19. Kripke D.F. Do hypnotics cause death and cancer? The burden of proof. Sleep Med. 2009, 10:275-276.
20. Kripke D.F., Klauber M.R., Wingard D.L., Fell R.L., Assmus J.D., Garfinkel L. Mortality hazard associated with prescription hypnotics. Biol. Psychiatry 1998, 43:687-693.
21. Kripke D.F., Langer R.D., Kline L.E. Hypnotics' association with mortality or cancer: a matched cohort study. BMJ Open 2012, 2:e000850.
22. Kryzhanovskaya L.A., Jeste D.V., Young C.A., Polzer J.P., Roddy T.E., Jansen J.F., Carlson J.L., Cavazzoni P.A. A review of treatment-emergent adverse events during olanzapine clinical trials in elderly patients with dementia. J. Clin. Psychiatry 2006, 67:933-945.
23. Lauterbach E.C. Use of psychotropic medication in Alzheimer's disease is associated with more rapid cognitive and functional decline. Evid. Based. Med. 2013, 18:e50.
24. Liperoti R., Pedone C., Corsonello A. Antipsychotics for the treatment of behavioral and psychological symptoms of dementia (BPSD). Curr. Neuropharmacol. 2008, 6:117-124.
25. Luyster F.S., Buysse D.J., Strollo P.J. Comorbid insomnia and obstructive sleep apnea: challenges for clinical practice and research. J. Clin. Sleep Med. 2010, 6:196-204.
26. Mallon L., Broman J.E., Hetta J. Is usage of hypnotics associated with mortality?. Sleep Med. 2009, 10:279-286.
27. Marras C., Gruneir A., Wang X., Fischer H., Gill S.S., Herrmann N., Anderson G.M., Hyson C., Rochon P.A. Antipsychotics and mortality in Parkinsonism. Am. J. Geriatr. Psychiatry 2012, 20:149-158.
28. Merlo J., Ostergren P.O., Mansson N.O., Hanson B.S., Ranstam J., Blennow G., Isacsson S.O., Melander A. Mortality in elderly men with low psychosocial coping resources using anxiolytic-hypnotic drugs. Scand. J. Public Health 2000, 28:294-297.
29. Montastruc F., Gardette V., Cantet C., Piau A., Lapeyre-Mestre M., Vellas B., Montastruc J.L., Andrieu S. Potentially inappropriate medication use among patients with Alzheimer disease in the REAL.FR cohort: be aware of atropinic and benzodiazepine drugs!. Eur. J. Clin. Pharmacol. 2013, 69:1589-1597.
30. Nguyen X.L., Chaskalovic J., Rakotonanahary D., Fleury B. Insomnia symptoms and CPAP compliance in OSAS patients: a descriptive study using data mining methods. Sleep Med. 2010, 11:777-784.
31. Ong J.C., Gress J.L., San Pedro-Salcedo M.G., Manber R. Frequency and predictors of obstructive sleep apnea among individuals with major depressive disorder and insomnia. J. Psychosom. Res. 2009, 67:135-141.
32. Pratt N., Roughead E.E., Salter A., Ryan P. Choice of observational study design impacts on measurement of antipsychotic risks in the elderly: a systematic review. BMC Med. Res. Methodol. 2012, 12:72.
33. Rintoul A.C., Dobbin M.D., Nielsen S., Degenhardt L., Drummer O.H. Recent increase in detection of alprazolam in Victorian heroin-related deaths. Med. J. Aust. 2013, 198:206-209.
34. Rosenberg P.B., Mielke M.M., Han D., Leoutsakos J.S., Lyketsos C.G., Rabins P.V., Zandi P.P., Breitner J.C., Norton M.C., Welsh-Bohmer K.A., Zuckerman I.H., Rattinger G.B., Green R.C., Corcoran C., Tschanz J.T. The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease. Int. J. Geriatr. Psychiatry 2012, 27:1248-1257.
35. Schneider L.S., Dagerman K.S., Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005, 294:1934-1943.
36. Schuld A., Kraus T., Haack M., Hinze-Selch D., Pollmacher T. Obstructive sleep apnea syndrome induced by clonazepam in a narcoleptic patient with REM-sleep-behavior disorder. J. Sleep Res. 1999, 8:321-322.
37. Sivertsen B., Omvik S., Pallesen S., Nordhus I.H., Bjorvatn B. Sleep and sleep disorders in chronic users of zopiclone and drug-free insomniacs. J. Clin. Sleep Med. 2009, 5:349-354.
38. Vigen C.L., Mack W.J., Keefe R.S., Sano M., Sultzer D.L., Stroup T.S., Dagerman K.S., Hsiao J.K., Lebowitz B.D., Lyketsos C.G., Tariot P.N., Zheng L., Schneider L.S. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. Am. J. Psychiatry 2011, 168:831-839.
39. Wang P.S., Schneeweiss S., Avorn J., Fischer M.A., Mogun H., Solomon D.H., Brookhart M.A. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N. Engl. J. Med. 2005, 353:2335-2341.
40. Wilson R.S., Tang Y., Aggarwal N.T., Gilley D.W., McCann J.J., Bienias J.L., Evans D.A. Hallucinations, cognitive decline, and death in Alzheimer's disease. Neuroepidemiology 2006, 26:68-75.
41. Wilton L.V., Heeley E.L., Pickering R.M., Shakir S.A. Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine. J. Psychopharmacol. 2001, 15:120-126.
42. Winkelmayer W.C., Mehta J., Wang P.S. Benzodiazepine use and mortality of incident dialysis patients in the United States. Kidney Int. 2007, 72:1388-1393.
43. Wu C.S., Wang S.C., Chang I.S., Lin K.M. The association between dementia and long-term use of benzodiazepine in the elderly: nested case-control study using claims data. Am. J. Geriatr. Psychiatry 2009, 17:614-620.